Salesforce Certified Agentforce Life Sciences Consultant : ALS-Con-201

Choose 1 option.
An Agentforce Life Sciences Consultant is asked to configure strategic distribution limits for Immunexis 50mg in a high-growth territory. The business requirement mandates that the total quantity available for the territory in the next quarter is capped, and individual field sales reps are restricted from handing off more than 50 units in a single visit.
Which administrative configuration should the consultant recommend?

• A. Create an Advanced Sample Limit Template and set the Maximum Quantity per Visit to 50 at the Healthcare Provider account level.
• B. Modify the Life Sciences Marketable Product record to set the Max Sample Order Quantity to 50 for the entire organization.
• C. Create a Territory Product Quantity Allocation record, define the Allocated Quantity for the territory, and set the Max Disbursement Limit Quantity to 50.

Choose 1 option.
A field sales rep bulk deletes several planned visits from the calendar for an upcoming week and then notices that two visits still appear on the calendar.
Why are these visits still visible?

• A. Visits where the rep is added as an attendee are currently set to appear on the calendar, so those visits remain visible even though they are managed by a colleague.
• B. The bulk delete action applies only to visits that match the selected account list, and the remaining visits are associated with accounts outside that list.
• C. The bulk delete action was performed from a filtered calendar view, and the remaining visits were not included in the deletion scope.

Choose 1 option.
Cumulus Pharma wants to ensure that whenever a field sales rep discusses a product during a visit, for example "Immunexis," the rep is required to record product-specific information before being allowed to submit the visit.
How should the Agentforce Life Sciences Consultant configure this requirement?

• A. Enable Require Discussion in Product Discussion Settings for the "Immunexis" product record.
• B. Create a validation rule on the Visit object that checks for discussions on the "Immunexis" product.
• C. Mark the Comments field as required on the Provider Visit Product Discussion page layout.

Choose 1 option.
Cumulus Pharma requires that once a field sales rep finalizes and submits a visit report, it must become immutable and no further edits should be allowed.
Which configuration ensures this behavior?

• A. Enable the VisitLockHandler and uncheck "Unlock submitted visit" in the Admin Console.
• B. Enable the VisitAutoSaveHandler and check "Allow edits after submission."
• C. Disable the StagePathPermissionsHandler and set the Visit Status to "Closed."

Choose 1 option.
Cumulus Pharma uses Agentforce Life Sciences for Customer Engagement to provide Account Summaries. The Agentforce Life Sciences Consultant configured a Cross-Object Field History Graph to include related Provider Visit and Medical Inquiry records. Key Account Managers report that summaries include all related data; however, field sales reps report that their summaries exclude visit and inquiry data. Both user groups have Read access to the underlying objects.
What is the cause of this issue?

• A. The field sales rep profile does not have View All permissions on these objects.
• B. The Cross-Object Field History Graph is not assigned to the field sales rep profile.
• C. The field sales rep has not been added to a Data 360 segment used for summarization.